199 related articles for article (PubMed ID: 33046520)
21. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
Izban KF; Alkan S; Singleton TP; Hsi ED
Arch Pathol Lab Med; 2000 Oct; 124(10):1457-62. PubMed ID: 11035575
[TBL] [Abstract][Full Text] [Related]
22. In situ hybridization and reverse transcription-polymerase chain reaction for cyclin D1 mRNA in the diagnosis of mantle cell lymphoma in paraffin-embedded tissues.
Athanasiou E; Kotoula V; Hytiroglou P; Kouidou S; Kaloutsi V; Papadimitriou CS
Mod Pathol; 2001 Feb; 14(2):62-71. PubMed ID: 11235907
[TBL] [Abstract][Full Text] [Related]
23. RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.
Weinstein S; Emmanuel R; Jacobi AM; Abraham A; Behlke MA; Sprague AG; Novobrantseva TI; Nagler A; Peer D
PLoS One; 2012; 7(8):e43343. PubMed ID: 22905260
[TBL] [Abstract][Full Text] [Related]
24. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms.
Chen YH; Gao J; Fan G; Peterson LC
Mod Pathol; 2010 Jan; 23(1):105-12. PubMed ID: 19801969
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional and post-transcriptional mechanisms induce cyclin-D1 over-expression in B-chronic lymphoproliferative disorders.
Sola B; Salaün V; Ballet JJ; Troussard X
Int J Cancer; 1999 Oct; 83(2):230-4. PubMed ID: 10471532
[TBL] [Abstract][Full Text] [Related]
26. Quantitation of cyclin D1 over-expression using competitive fluorescent reverse transcription polymerase chain reaction: a tool for the differential diagnosis of mantle cell lymphoma.
Wickham CL; Armitage H; Joyner MV; Sarsfield P; Boyce M; Wilkins BS; Jones DB; Ellard S
Med Oncol; 2003; 20(1):77-85. PubMed ID: 12665688
[TBL] [Abstract][Full Text] [Related]
27. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Lo RK; Kwong YL
Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
[TBL] [Abstract][Full Text] [Related]
28. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.
Slotta-Huspenina J; Koch I; de Leval L; Keller G; Klier M; Bink K; Kremer M; Raffeld M; Fend F; Quintanilla-Martinez L
Haematologica; 2012 Sep; 97(9):1422-30. PubMed ID: 22315488
[TBL] [Abstract][Full Text] [Related]
29. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.
Kurita D; Takeuchi K; Kobayashi S; Hojo A; Uchino Y; Sakagami M; Ohtake S; Takahashi H; Miura K; Iriyama N; Sugitani M; Miyoshi H; Hatta Y; Ohshima K; Takei M
Virchows Arch; 2016 Oct; 469(4):471-6. PubMed ID: 27457074
[TBL] [Abstract][Full Text] [Related]
30. Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1.
Babosova O; Kapralova K; Raskova Kafkova L; Korinek V; Divoky V; Prchal JT; Lanikova L
J Cell Mol Med; 2019 Nov; 23(11):7785-7795. PubMed ID: 31517438
[TBL] [Abstract][Full Text] [Related]
31. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.
Salaverria I; Zettl A; Beà S; Moreno V; Valls J; Hartmann E; Ott G; Wright G; Lopez-Guillermo A; Chan WC; Weisenburger DD; Gascoyne RD; Grogan TM; Delabie J; Jaffe ES; Montserrat E; Muller-Hermelink HK; Staudt LM; Rosenwald A; Campo E
J Clin Oncol; 2007 Apr; 25(10):1216-22. PubMed ID: 17296973
[TBL] [Abstract][Full Text] [Related]
32. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.
Chuang SS; Huang WT; Hsieh PP; Tseng HH; Campo E; Colomer D; Ye H; Lu CL; Chang HM; Cho CY; Huang SH; Lu YC; Wu JD
Pathol Int; 2006 Aug; 56(8):440-8. PubMed ID: 16872438
[TBL] [Abstract][Full Text] [Related]
33. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.
Islam TC; Asplund AC; Lindvall JM; Nygren L; Liden J; Kimby E; Christensson B; Smith CI; Sander B
Leukemia; 2003 Sep; 17(9):1880-90. PubMed ID: 12970790
[TBL] [Abstract][Full Text] [Related]
34. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.
Kawamata N; Chen J; Koeffler HP
Blood; 2007 Oct; 110(7):2667-73. PubMed ID: 17606765
[TBL] [Abstract][Full Text] [Related]
35. Cyclin D1 transcriptional activation in MCL.
Beà S
Blood; 2014 Mar; 123(13):1979-80. PubMed ID: 24677400
[TBL] [Abstract][Full Text] [Related]
36. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Chiarle R; Budel LM; Skolnik J; Frizzera G; Chilosi M; Corato A; Pizzolo G; Magidson J; Montagnoli A; Pagano M; Maes B; De Wolf-Peeters C; Inghirami G
Blood; 2000 Jan; 95(2):619-26. PubMed ID: 10627471
[TBL] [Abstract][Full Text] [Related]
37. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas.
Medeiros LJ; Hai S; Thomazy VA; Estalilla OC; Romaguera J; Luthra R
Mod Pathol; 2002 May; 15(5):556-64. PubMed ID: 12011261
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia.
Miranda RN; Briggs RC; Kinney MC; Veno PA; Hammer RD; Cousar JB
Mod Pathol; 2000 Dec; 13(12):1308-14. PubMed ID: 11144927
[TBL] [Abstract][Full Text] [Related]
39. Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
Isaac KM; Portell CA; Williams ME
Curr Oncol Rep; 2021 Jul; 23(9):102. PubMed ID: 34269910
[TBL] [Abstract][Full Text] [Related]
40. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
Rosenwald A; Wright G; Wiestner A; Chan WC; Connors JM; Campo E; Gascoyne RD; Grogan TM; Muller-Hermelink HK; Smeland EB; Chiorazzi M; Giltnane JM; Hurt EM; Zhao H; Averett L; Henrickson S; Yang L; Powell J; Wilson WH; Jaffe ES; Simon R; Klausner RD; Montserrat E; Bosch F; Greiner TC; Weisenburger DD; Sanger WG; Dave BJ; Lynch JC; Vose J; Armitage JO; Fisher RI; Miller TP; LeBlanc M; Ott G; Kvaloy S; Holte H; Delabie J; Staudt LM
Cancer Cell; 2003 Feb; 3(2):185-97. PubMed ID: 12620412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
